This transcript is automatically generated
I'm on the part network.
-- -- -- -- -- -- -- -- -- Morning we're watching shares than it is today that stock is soaring after the company -- a federal advisory panel has overwhelmingly backed its weight loss drug Q next up.
The move could lead to FDA approval of the new prescription obesity pill for the first time in more than ten years.
The FDA had rejected Kenexa previously due to safety concerns most patients lost nearly 10% of their overall weight.
After a year on the drug but the advisory panel stresses -- this must be required.
To conduct a large follow up study of the -- effects on the heart there an estimated 75 million obese adults in the United States.
Looking at futures this morning you can see arrows are pointing -- -- features higher by twenty points.
Imus in the morning continues right now on Fox Business giving you the power across this.